Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + pelareorep
- Development stage
- Unknown
- Lead developer
- Oncolytics Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Combination of paclitaxel (a chemotherapy agent) and pelareorep (an oncolytic reovirus). Pelareorep is a type 3 reovirus that invades and lyses tumor cells and promotes an inflammatory tumor microenvironment. When combined with paclitaxel, it has shown significant improvements in overall survival, progression-free survival, and response rates in HR+/HER2- metastatic breast cancer patients compared to paclitaxel alone.
- Brand names
- ReolysinTaxol
- Other names
- pelareoreppaclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))JAM-A (Junctional adhesion molecule A)SA (Sialic acid)
Beyond the preview
Go deeper on paclitaxel + pelareorep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + pelareorep.